Cargando…

Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial

Pentraxin 2 (PTX-2; serum amyloid P component), a circulating endogenous regulator of the inflammatory response to tissue injury and fibrosis, is reduced in patients with myelofibrosis (MF). Zinpentraxin alfa (RO7490677, PRM-151) is a recombinant form of PTX-2 that has shown preclinical antifibrotic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verstovsek, Srdan, Foltz, Lynda, Gupta, Vikas, Hasserjian, Robert, Manshouri, Taghi, Mascarenhas, John, Mesa, Ruben, Pozdnyakova, Olga, Ritchie, Ellen, Veletic, Ivo, Gamel, Katia, Hamidi, Habib, Han, Lyrialle, Higgins, Brian, Trunzer, Kerstin, Uguen, Marianne, Wang, Dao, El-Galaly, Tarec Christoffer, Todorov, Boyan, Gotlib, Jason
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2023
Materias:	Article - Myeloproliferative Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543197/ https://www.ncbi.nlm.nih.gov/pubmed/37165840 http://dx.doi.org/10.3324/haematol.2022.282411

Ejemplares similares

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
por: Verstovsek, Srdan, et al.
Publicado: (2021)

Ruxolitinib: Long-Term Management of Patients with Myelofibrosis and Future Directions in the Treatment of Myeloproliferative Neoplasms
por: Yacoub, A., et al.
Publicado: (2014)

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
por: Ostojic, Alen, et al.
Publicado: (2012)

Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis
por: Veletic, Ivo, et al.
Publicado: (2020)

Myelofibrosis
por: Passamonti, Francesco, et al.
Publicado: (2023)

GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes
por: Manshouri, Taghi, et al.
Publicado: (2022)

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
por: Bryan, Jeffrey C., et al.
Publicado: (2016)

MF management
por: Bose, Prithviraj, et al.
Publicado: (2019)

Primary myelofibrosis marrow-derived CD14(+)/CD34(-) monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes
por: Manshouri, Taghi, et al.
Publicado: (2019)

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
por: Verstovsek, Srdan, et al.
Publicado: (2013)

Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib?
por: Caocci, Giovanni, et al.
Publicado: (2021)

Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis
por: Murthy, Guru Subramanian Guru, et al.
Publicado: (2023)

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
por: Rajasekaran, Arun, et al.
Publicado: (2015)

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
por: Gupta, Vikas, et al.
Publicado: (2023)

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
por: Mascarenhas, John O., et al.
Publicado: (2022)

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
por: Verstovsek, Srdan, et al.
Publicado: (2017)

Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval
por: Verstovsek, Srdan, et al.
Publicado: (2021)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
por: Gerds, Aaron T., et al.
Publicado: (2022)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
por: Kvasnicka, Hans Michael, et al.
Publicado: (2018)

Sustained‐release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis
por: Verstovsek, Srdan, et al.
Publicado: (2018)

MPN-433: Outcomes of COVID-19 in Hematopoietic Stem Cell Transplant Recipients: A Single-Institution, Observational Study
por: Dwabe, Sami, et al.
Publicado: (2021)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2023)

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
por: Harrison, Claire N., et al.
Publicado: (2020)

P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS
por: Kremyanskaya, Marina, et al.
Publicado: (2023)

Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
por: Jamieson, Catriona, et al.
Publicado: (2015)

How I manage anemia related to myelofibrosis and its treatment regimens
por: Verstovsek, Srdan
Publicado: (2023)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
por: Harrison, C., et al.
Publicado: (2022)

P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
por: Gupta, V., et al.
Publicado: (2022)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
por: Manduzio, Palma
Publicado: (2017)

P1025: A PILOT STUDY OF THE ANTI-SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS.
por: Bose, Prithviraj, et al.
Publicado: (2023)

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
por: Couban, Stephen, et al.
Publicado: (2018)

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
por: Talpaz, Moshe, et al.
Publicado: (2013)

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
por: Chifotides, Helen T., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7qr9q461hd6a3b1ge90c28vcik